Quick Comparison
| ALCAR | Phenibut | |
|---|---|---|
| Half-Life | 4-5 hours | 5-6 hours |
| Typical Dosage | Standard: 500-2000 mg daily in 1-2 doses. For cognitive support: 1000-2000 mg daily. For neuropathy: 1500-3000 mg daily. Take in the morning — may be mildly stimulating. | Standard: 250-1000 mg on an empty stomach, no more than 1-2 times per week. NEVER use daily — tolerance and dependence develop within 3-5 days of consecutive use. Onset: 2-4 hours (slow). Do not exceed 2000 mg per occasion. |
| Administration | Oral (capsules, powder). Well-absorbed on an empty stomach. | Oral (powder, capsules). Take on an empty stomach — food significantly reduces absorption. Slow onset (2-4 hours). |
| Research Papers | 9 papers | 10 papers |
| Categories |
Mechanism of Action
ALCAR
ALCAR crosses the blood-brain barrier via the organic cation transporter (OCTN2) more effectively than L-carnitine. In neurons, it is hydrolyzed by carnitine acetyltransferase to donate its acetyl group to coenzyme A, forming acetyl-CoA—which can then be used for acetylcholine synthesis via choline acetyltransferase, effectively providing raw material for the memory neurotransmitter. ALCAR also transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system for beta-oxidation and ATP production. ALCAR activates nerve growth factor (NGF) signaling, possibly through modulation of NGF receptor (TrkA) expression or downstream MAPK/ERK pathways. It has antioxidant properties, reducing lipid peroxidation in mitochondrial membranes and scavenging free radicals. These mechanisms support cognitive function and neuroprotection.
Phenibut
Phenibut is a structural analog of GABA with a phenyl ring that confers lipophilicity and allows blood-brain barrier penetration (unlike GABA itself). It acts as a GABA-B receptor agonist, binding to the GABAB1/GABAB2 heterodimer and activating Gi/o-coupled signaling (similar to baclofen), producing anxiolytic, muscle relaxant, and sedative effects through inhibition of adenylyl cyclase and modulation of potassium and calcium channels. Phenibut also blocks the alpha-2-delta-1 and alpha-2-delta-2 subunits of voltage-gated calcium channels, reducing presynaptic calcium influx and neurotransmitter release (similar to gabapentin/pregabalin). The dual mechanism—GABA-B agonism dampening inhibitory interneurons and calcium channel blockade reducing excitatory transmission—produces potent anti-anxiety and sleep-promoting effects. Rapid tolerance develops due to receptor downregulation.
Risks & Safety
ALCAR
Common
Nausea, fishy body odor, restlessness, gastrointestinal discomfort.
Serious
May increase agitation in Alzheimer's patients. TMAO production may be a cardiovascular concern with chronic high doses.
Rare
Seizures in susceptible individuals, increased thyroid activity.
Phenibut
Common
Drowsiness, dizziness, nausea, tolerance with repeated use.
Serious
Physical dependence develops rapidly with daily use. Withdrawal can be severe and dangerous (anxiety, insomnia, psychosis, seizures). Respiratory depression when combined with alcohol or other CNS depressants.
Rare
Hallucinations, severe rebound anxiety, suicidal ideation during withdrawal.
Full Profiles
ALCAR →
Acetyl-L-Carnitine is an acetylated form of L-Carnitine that crosses the blood-brain barrier more effectively than regular L-Carnitine. In the brain, it donates its acetyl group for acetylcholine synthesis and supports mitochondrial fatty acid oxidation for energy. Used clinically for age-related cognitive decline, depression, and diabetic neuropathy.
Phenibut →
A GABA-B agonist and alpha-2-delta voltage-gated calcium channel blocker developed in Russia for anxiety, insomnia, and PTSD. It crosses the blood-brain barrier (unlike GABA supplements) and produces potent anxiolytic and social confidence effects. However, it carries significant addiction and withdrawal risks — tolerance develops within days of daily use, and withdrawal can be severe.